Inovio Pharmaceuticals filed an 8-K press release on November 2, 2026, announcing its participation in two scientific conferences in November 2026 to present its DNA medicine research, including data on INO-D001 for Hemophilia A.

Key Highlights

  • Two conferences: Inovio disclosed plans to participate in the Soft Bones Third International Scientific Meeting on Hypophosphatasia in New York and the World Federation of Hemophilia NTGT Workshop in Montreal.
  • Hypophosphatasia presentation: The title disclosed is "Rare Disease Protein Replacement Therapeutics: The Transformational Potential of Next-Gen DNA Medicine," scheduled for Sunday, November 8.
  • Hemophilia A presentation: A presentation on INO-D001 for Hemophilia A is scheduled for Thursday, November 12, at the World Federation of Hemophilia workshop.
  • Exchange and ticker: Inovio trades on NASDAQ:INO.
  • Company focus: According to the filing, Inovio is "a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases."

Inovio's DNA Medicine Pipeline Featured at November 2026 Scientific Events

According to the filing, Inovio is a Plymouth Meeting, Pennsylvania-based biotechnology company whose technology platform centers on optimizing "the design and delivery of innovative DNA medicines that enable the body to manufacture its own disease-fighting tools." The company's pipeline spans HPV-related diseases, cancer, and infectious diseases, and the two announced presentations extend its disclosed research into rare and hemophilia-related conditions.

The first presentation, titled "Rare Disease Protein Replacement Therapeutics: The Transformational Potential of Next-Gen DNA Medicine," is scheduled for November 8 at the Soft Bones Third International Scientific Meeting on Hypophosphatasia in New York. The second, focused specifically on INO-D001 for Hemophilia A, is set for November 12 at the World Federation of Hemophilia New Technology and Gene Therapy Workshop in Montreal. The filing noted that abstracts and presentations will be added to the company's events page if available.

What Was Disclosed

Inovio announced on November 2, 2026, that it will present at two scientific conferences in November 2026, one addressing hypophosphatasia and one addressing Hemophilia A via its INO-D001 candidate, with both presentations reflecting the company's stated DNA medicine platform strategy.